KalVista Q3 fiscal 2025: $253.2M cash, sebetralstat regulatory progress; PDUFA June 17

KalVista Pharmaceuticals, Inc.

No revenue; R&D expense $12.6M (down from $22.5M YoY); G&A $30.3M (up from $10.6M) due to pre-commercial activities.
Cash, cash equivalents and marketable securities of $253.2M as of Jan 31, 2025.
Sebetralstat NDA submitted in Japan, orphan drug designation granted; U.S. PDUFA date June 17, 2025.
Raised $160M gross proceeds in Nov 2024 via synthetic royalty financing and equity offerings to fund launch.
Field sales team onboarded; Jeb Ledell appointed COO; new data presented on laryngeal attacks, adolescents, and LTP patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.